Lietinib Tablets (trade name: Aoyixin) is a prescription-only medication and must be used under the guidance of a physician. Below is relevant information regarding its procurement:
Market Approval Status
Lietinib Tablets was approved for marketing in China in January 2025. Manufactured by Jiangsu Aosaikang Pharmaceutical Co., Ltd., it holds the National Medicine Approval Number H20250004.
Indications
This medication is indicated for adult patients with non-small cell lung cancer (NSCLC) in the following two scenarios:
First-line treatment for patients with EGFR exon 19 deletion or exon 21 (L858R) substitution mutation.
Second-line treatment for patients with disease progression after prior EGFR-TKI therapy and confirmed positive EGFR T790M mutation upon testing.
Procurement Methods
As a prescription drug, Lietinib Tablets can only be purchased through legitimate channels with a valid physician’s prescription. The following access routes are available:
Hospital Pharmacies
Oncology departments or in-house pharmacies of treating hospitals typically stock this medication. It is advisable to consult your attending physician first.
Licensed Pharmacies
Some large chain pharmacies and pharmacies qualified for prescription drug sales may offer this product. For instance, platforms like Hunan Pharmaceutical Service Network display relevant sales information.
Online Platforms
Certain legitimate pharmaceutical e-commerce platforms support home delivery following online consultation and prescription verification. Ensure that the platform holds valid operating qualifications.
Price Reference
Based on market data, the approximate price for a pack of 80mg × 20 tablets is USD 980. However, the actual price is subject to fluctuations depending on regional policies, hospital or pharmacy pricing regulations. It is recommended to refer to the local listed price or real-time quotes from pharmacies.
Precautions
Genetic Testing Requirement: EGFR mutation status must be confirmed through genetic testing prior to medication initiation, and treatment should be administered only after evaluation by a qualified physician.
Adverse Reactions: Common adverse reactions include diarrhea and rash, but the medication is generally well-tolerated by most patients.
